Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.

Read, J S; Best, B M; Stek, A M; Hu, C; Capparelli, E V; Holland, D T; Burchett, S K; Smith, M E; Sheeran, E C; Shearer, W T; Febo, I; Mirochnick, M

Read, J S; Best, B M; Stek, A M; Hu, C; Capparelli, E V; Holland, D T; Burchett, S K; Smith, M E; Sheeran, E C; Shearer, W T; Febo, I; Mirochnick, M.

Affiliation

Read JS; Pediatric, Adolescent and Maternal AIDS Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-7510, USA. jennifer_read@nih.gov

HIV Med ; 9(10): 875-82, 2008 Nov.

Article in En | MEDLINE | ID: mdl-18795962

Subject(s)

HIV Infections/drug therapy; HIV Protease Inhibitors/pharmacokinetics; HIV-1; Nelfinavir/pharmacokinetics; Pregnancy Complications, Infectious/drug therapy; Adolescent; Adult; Area Under Curve; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infections/metabolism; HIV Protease Inhibitors/administration & dosage; Humans; Infant, Newborn; Nelfinavir/administration & dosage; Pregnancy; Pregnancy Complications, Infectious/metabolism; Puerperal Infection/drug therapy; Puerperal Infection/metabolism; RNA, Viral; Viral Load; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Pregnancy Complications, Infectious / HIV Infections / HIV-1 / HIV Protease Inhibitors / Nelfinavir Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Newborn / Pregnancy Language: En Year: 2008 Type: Article

Fulltext

XML

PubMed Links

Search on Google